Takeda is preparing for a substantial drop in revenue as two of its major drugs approach patent cliffs this summer. The first is the company’s attention deficit hyperactivity disorder (ADHD) drug Vyvanse, which will lose US exclusivity this August. Takeda’s hypertension medication Azilva will lose exclusivity in Japan this June. The combined hit of the two losses is expected to reach $2.4 billion (330 billion yen).
According to Fraiser Kansteiner, “The coming year will be “challenging” in the face of those patent expirations, Takeda CEO Christophe Weber told analysts on an earnings call this week. Still, the company expects established drugs and new launches to “largely offset” the brunt of the patent expiration hit. Takeda is enjoying positive momentum on a range of medicines such as Entyvio, Takhzyro, Livtencity and its plasma-derived therapies. Plus, the company expects to see a “meaningful contribution” from its dengue vaccine Qdenga.”
To read more, click here.
(Source: Fierce Pharma, May 12th, 2023)